Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Asciminib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.98 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asciminib SCHEMBL22656445 | 1.00 | ABL1 (0.98) | ABL1BCRKCNH2CRBN | |
| Asciminib SCHEMBL29429820 | 0.99 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| Asciminib SCHEMBL15388306 | 0.99 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| Asciminib SCHEMBL15388308 | 0.99 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| Asciminib SCHEMBL15388554 | 0.99 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| SCHEMBL16678695 | 0.95 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| SCHEMBL15393486 | 0.95 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| SCHEMBL15393510 | 0.95 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| SCHEMBL15393484 | 0.95 | ABL1 (1.00) | ABL1BCRKCNH2CRBN | |
| SCHEMBL15393374 | 0.94 | ABL1 (1.00) | ABL1BCRKCNH2CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3969445-B1 | PROCESS FOR THE PREPARATION OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDE | NOVARTIS AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| EP-3969445-A1 | CHEMICAL PROCESS | Novartis AG (CH) | 2022-03-23 | — | — | EP | disclosed |
| CN-114096529-A | Chemical process | 诺华股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-11236070-B2 | Chemical process | NOVARTIS AG (CH) | 2022-02-01 | — | — | US | disclosed |
| US-20200361903-A1 | CHEMICAL PROCESS | NOVARTIS PHARMA AG (CH) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361903-A1 | CHEMICAL PROCESS | CYP3A4, CYP4B1, CYP4F3 | ABL1 28/4885BCR 2682/4885KCNH2 914/4885 |
| US-11236070-B2 | Chemical process | CYP3A4, CYP4B1, CYP4F3 | ABL1 28/4885BCR 2682/4885KCNH2 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.